Pharmaceutical Innovation: Is It Really Rewarded?

Introduction Governments in the world's largest pharmaceutical markets clearly have an interest in promoting access to innovative medicines, but the relatively high price of many novel drugs can place a heavy fi nancial burden on overtaxed health care systems. Thus, the essential challenge for governments and other payers is to strike a balance between the benefi ts and costs of making innovative medicines more widely available. Get the Answers You Need to Shape Your Strategy The European Commission wants to balance strict price controls and free market pricing. What initiatives . has the EU undertaken to achieve this balance? Which EU markets have the strictest constraints on pharmaceutical pricing? Are new policies likely to improve or worsen the climate for pharmaceutical companies? Recently, the Japanese government has taken action intended to make premiums for innovation more generous . and more attainable. What price reforms has the government made? Are they likely to in fact encourage innovation? Will the new price premiums be achievable? In the United States, the increasing focus on drug prices will prompt more payers to adopt evidence-based . formularies. How is formulary decision making evolving in the private sector? How is Medicare now encouraging health economic research? Scope EU innovation initiatives: . a review of recent initiatives by the EU in support of innovative medicines in Europe. Outlook and implications for the pharmaceutical industry: . the future of reimbursement for innovative drugs in the EU, Japan, and the United States. Detailed analysis of pricing and reimbursement in the major markets: . an examination of how health care payers in seven leading pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom, Japan, and United States) approach the pricing and reimbursement of innovative drugs. Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Companies and Organizations Mentioned in This Spectrum Report

Academy of Managed Care Pharmacy
Agency for Healthcare Research and Quality
Association of the British Pharmaceutical Industry
Astellas
Bayer
Chugai
Daiichi-Sankyo
European Federation of Pharmaceutical Industries
and Associations Federation of Pharmaceutical Manufacturers’
Associations of Japan Fujisawa
Genentech
Genzyme
German Association of Research-Based
Pharmaceutical Companies GlaxoSmithKline
High-Level Group on Innovation and the Provision
of Medicines (The G10 Medicines Group) Italian Pharmaceutical Agency
Merck & Co.
Mitsubishi
Novartis
Pfi zer
Pharmaceutical Forum
Pharmaceutical Research and Manufacturers of
America Roche
Sanofi -Aventis
Sanofi -Aventis Deutschland
Schering-Plough
Toyamakagaku